Intrahepatic Cholangiocarcinoma (ICCA)-Epidemiology Forecast–2030

DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Intrahepatic Cholangiocarcinoma (ICCA) Disease Understanding
Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).

Based on the macroscopic tumor growth pattern ICCA can be classified as mass-forming type, periductal infiltrating type, or intraductal growing type according to the classification of the Liver Cancer Study Group of Japan. It can also be classified into two types according to the site of involvement and histologic features: perihilar large duct ICCA, which involves the intrahepatic large bile ducts, and peripheral small duct ICCA, which involves the intrahepatic small bile ducts

Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Intrahepatic Cholangiocarcinoma (ICCA) Detailed Epidemiology Segmentation
• In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.
• The United States contributes the largest share with 3,639 incident cases in 2017, acquiring near about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.
• ICCA is more common in males as compared to females. In 2017, males contributed to 50.9% of all incident cases of ICCA in the US.
• OId age patients are at higher risk of developing ICCA. In the US, the age group 70–79 years contributed to 28% of the ICCA incident cases in 2017.
• ICCA is most commonly diagnosed in later stages of cancer. In 2017, 69% of the cases were diagnosed in stage III and stage IV in the US.
• Biomarkers such as VEGF overexpression, IDH1/IDH2 mutation, and FGFR translocations are most commonly seen in ICCA. They were found in 28%, 16%, and 15% of the ICCA cases in 2017.
• In EU5 countries, Italy contributed the largest share in ICCA incident cases, followed by Germany. In contrast, Spain accounted for the lowest share in ICCA incident cases.
• In 2017, the incident population of ICCA in Japan was 2,731.

Scope of the Report
• The report covers the descriptive overview of ICCA, explaining its signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of ICCA.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA.

Report Highlights
• 11-Year Forecast of ICCA
• 7MM Coverage
• Total Incident Cases of ICCA
• Gender-specific Incident Cases of ICCA
• Age-specific Incident Cases of ICCA
• Stage-specific Incident Cases of ICCA
• Biomarker-specific Incident Cases of ICCA

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of ICCA?
• What is the historical ICCA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of ICCA at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ICCA?
• Out of the above-mentioned countries, which country would have the highest incident population of ICCA during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The ICCA report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM ICCA epidemiology forecast.
• The ICCA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The ICCA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030